{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T12:49:42Z","timestamp":1772282982485,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Centre Egypt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Liver necrosis is the irreversible loss of hepatocytes through toxin-induced injury, ischemia, or infection to produce organ dysfunction. It is a significant pathological marker in many liver disorders, including cirrhosis, and hepatitis, and contributes to organ failure and general systemic effects. This research aims to evaluate the protective effects of a newly synthesized compound named 1-(5-((1-(1-(4-((4-(4-(1-((5-acetyl-3-phenyl-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono)ethyl)-5-methyl-1H-1,2,3-triazol-1-yl)phenyl)sulfonyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)ethylidene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)ethan-1-one (TTTE) sulfone-bis chalcone derivative on liver necrosis caused by TAA therapy using murine model. The research investigates optimal cellular pathways which demonstrate the therapeutic properties of TTTE as a potential treatment for liver injuries. The newly prepared compound TTTE was successfully characterized by Fourier transform infrared spectroscopy (FT-IR), proton nuclear magnetic resonance (1H-NMR) spectroscopy, carbon-13 nuclear magnetic resonance (13C-NMR), The safety of the as-prepared compound TTTE was determined based on weight changes and the behaviors in all the groups were monitored for 21 days. The effect of treatment of TTTE at different doses (300, 200, and 100\u00a0mg\/kg B.W.) was studied. High-dose TTTE revealed a 62.5% survival rate compared to the untreated TAA group (40%). Molecular analysis exhibited that high-dose TTTE downregulated Cas-3, TIMP-1, and proinflammatory cytokines (TNF-\u03b1, NF-\u03baB, and IL-6) compared to untreated TAA. Results of histopathological and IHC examinations exhibited high TTTE dose have no signs of liver injury with suppression in TGF-\u03b2 expression as a result of anti-inflammatory response. Our study concluded that the synthesized compound, TTTE has a potential therapeutic strategy in mitigating liver necrosis. <\/jats:p>","DOI":"10.1038\/s41598-025-02483-0","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T13:08:30Z","timestamp":1747746510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Towards novel liver injury therapies based on design, synthesis and therapeutic efficacy of novel sulfone bis-compound on liver necrosis"],"prefix":"10.1038","volume":"15","author":[{"given":"Huda R. M.","family":"Rashdan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hend","family":"Okasha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"2483_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.09.014","author":"SK Asrani","year":"2019","unstructured":"Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, https:\/\/doi.org\/10.1016\/j.jhep.2018.09.014 (2019).","journal-title":"J. Hepatol."},{"key":"2483_CR2","volume-title":"Global Hepatitis Report 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global Hepatitis Report 2017 (World Health Organization, 2017)."},{"key":"2483_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6","author":"DQ Huang","year":"2021","unstructured":"Huang, D. Q., El-Serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, https:\/\/doi.org\/10.1038\/s41575-020-00381-6 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2483_CR4","doi-asserted-by":"publisher","DOI":"10.15171\/ipp.2018.18","author":"F Nojoomi","year":"2018","unstructured":"Nojoomi, F., Ghasemian, A., Fallahi, S. & Hasanvand, F. High prevalence and risk factors of hepatitis B, C and E infections among Middle Eastern countries. Immunopathol. Persa 4, https:\/\/doi.org\/10.15171\/ipp.2018.18 (2018).","journal-title":"Immunopathol. Persa"},{"key":"2483_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.5455\/2320-1770.ijrcog20140938","volume":"3","author":"P Ramalingappa","year":"2014","unstructured":"Ramalingappa, P., Aradhya, H., Hanumantharaya, N. & Bolarigowda, P. Alpha Methyldopa induced hepatotoxicity in pregnancy. Int. J. Reprod. Contracept. Obstet. Gynecol. 3, 805\u2013807. https:\/\/doi.org\/10.5455\/2320-1770.ijrcog20140938 (2014).","journal-title":"Int. J. Reprod. Contracept. Obstet. Gynecol."},{"key":"2483_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2017.05.016","volume":"121","author":"K B\u00f6ttcher","year":"2017","unstructured":"B\u00f6ttcher, K. & Pinzani, M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Adv. Drug Deliv Rev. 121, 3\u20138. https:\/\/doi.org\/10.1016\/j.addr.2017.05.016 (2017).","journal-title":"Adv. Drug Deliv Rev."},{"key":"2483_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200009000-00024","author":"R Chatila","year":"2000","unstructured":"Chatila, R. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. J. Clin. Gastroenterol. 31, https:\/\/doi.org\/10.1097\/00004836-200009000-00024 (2000).","journal-title":"J. Clin. Gastroenterol."},{"key":"2483_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2015.00178","author":"H Weng","year":"2015","unstructured":"Weng, H. et al. Two sides of one coin: massive hepatic necrosis and progenitor cell-mediated regeneration in acute liver failure. Front. Physiol. 6, https:\/\/doi.org\/10.3389\/fphys.2015.00178 (2015).","journal-title":"Front. Physiol."},{"key":"2483_CR9","doi-asserted-by":"publisher","first-page":"590","DOI":"10.30856\/th.jhep2018vol1iss1_63","volume":"67","author":"F Rennebaum","year":"2023","unstructured":"Rennebaum, F. & Trebicka, J. Acute liver failure. Tagliche Prax. 67, 590\u2013600. https:\/\/doi.org\/10.30856\/th.jhep2018vol1iss1_63 (2023).","journal-title":"Tagliche Prax"},{"key":"2483_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00003088-198207020-00001","volume":"7","author":"JAH Forrest","year":"1982","unstructured":"Forrest, J. A. H., Clements, J. A. & Prescott, L. F. Clinical pharmacokinetics of Paracetamol. Clin. Pharmacokinet. 7, 93\u2013107. https:\/\/doi.org\/10.2165\/00003088-198207020-00001 (1982).","journal-title":"Clin. Pharmacokinet."},{"key":"2483_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.20884\/1.jm.2022.17.1.5595","volume":"17","author":"IWT Aryasa","year":"2022","unstructured":"Aryasa, I. W. T. & Noviandri, I. Voltammetric determination of Paracetamol with carbon paste electrode modified with molecularly imprinted electropolymer. Molekul 17, 30\u201338. https:\/\/doi.org\/10.20884\/1.jm.2022.17.1.5595 (2022).","journal-title":"Molekul"},{"key":"2483_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/00498250802512830","volume":"39","author":"JE Laine","year":"2009","unstructured":"Laine, J. E., Auriola, S., Pasanen, M. & Juvonen, R. O. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 39, 11\u201321. https:\/\/doi.org\/10.1080\/00498250802512830 (2009).","journal-title":"Xenobiotica"},{"key":"2483_CR13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3390\/biomedicines9081014","volume":"9","author":"Y Yan","year":"2021","unstructured":"Yan, Y., Zeng, J., Xing, L. & Li, C. Extra- and Intra-Cellular mechanisms of hepatic stellate cell activation. Biomedicines 9, 1014. https:\/\/doi.org\/10.3390\/biomedicines9081014 (2021).","journal-title":"Biomedicines"},{"key":"2483_CR14","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.12998\/WJCC.V10.I12.3662","volume":"10","author":"DV Garbuzenko","year":"2022","unstructured":"Garbuzenko, D. V. Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis. World J. Clin. Cases. 10, 3662. https:\/\/doi.org\/10.12998\/WJCC.V10.I12.3662 (2022).","journal-title":"World J. Clin. Cases"},{"key":"2483_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/954050","volume":"2013","author":"H Abdelrahman","year":"2013","unstructured":"Abdelrahman, H., Ajaj, A., Atique, S., El-Menyar, A. & Al-Thani, H. Conservative management of major liver necrosis after angioembolization in a patient with blunt trauma. Case Rep. Surg. 2013, 1\u20134. https:\/\/doi.org\/10.1155\/2013\/954050 (2013).","journal-title":"Case Rep. Surg."},{"key":"2483_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/mc.23874","volume":"64","author":"L Zou","year":"2025","unstructured":"Zou, L. et al. Downregulation of SLC7A11 by Bis(4-Hydroxy-3,5-Dimethylphenyl) sulfone induces ferroptosis in hepatocellular carcinoma cell. Mol. Carcinog. 64, 580\u2013596. https:\/\/doi.org\/10.1002\/mc.23874 (2025).","journal-title":"Mol. Carcinog."},{"key":"2483_CR17","doi-asserted-by":"publisher","first-page":"116306","DOI":"10.1016\/j.ejmech.2024.116306","volume":"269","author":"J Mati\u0107","year":"2024","unstructured":"Mati\u0107, J. et al. Sulfone-based human liver pyruvate kinase inhibitors - Design, synthesis and in vitro bioactivity. Eur. J. Med. Chem. 269, 116306. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116306 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2483_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclepro.2023.139932","author":"EK Radwan","year":"2024","unstructured":"Radwan, E. K. et al. Synthesis and application of a new multi-functional biopolymer-based aerogel loaded with bistriazole derivative as highly efficient adsorbent and disinfectant. J. Clean. Prod. 434. https:\/\/doi.org\/10.1016\/j.jclepro.2023.139932 (2024).","journal-title":"J. Clean. Prod."},{"key":"2483_CR19","unstructured":"hanaa, F. et al. Design, efficient synthesis, mechanism of reaction and antiproliferative activity against cancer and normal cell lines of a novel class of fused pyrimidine derivatives, Acta Pol. Pharm. Res. 75 (2018)."},{"key":"2483_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7897\/2277-4343.1404130","volume":"14","author":"GS Rameshwar","year":"2023","unstructured":"Rameshwar, G. S., Venkatrao, P. U., Vithalrao, N. A. & Pramodrao, A. M. OECD GUIDELINES FOR ACUTE ORAL TOXICITY STUDIES: AN OVERVIEW. Int. J. Res. Ayurveda Pharm. 14, 137\u2013140. https:\/\/doi.org\/10.7897\/2277-4343.1404130 (2023).","journal-title":"Int. J. Res. Ayurveda Pharm."},{"key":"2483_CR21","doi-asserted-by":"publisher","first-page":"6524658","DOI":"10.1155\/2021\/6524658","volume":"2021","author":"PNT Tran","year":"2021","unstructured":"Tran, P. N. T. & Tran, T. T. N. Evaluation of acute and subchronic toxicity induced by the crude ethanol extract of Plukenetia volubilis Linneo leaves in Swiss albino mice. Biomed. Res. Int. 2021, 6524658. https:\/\/doi.org\/10.1155\/2021\/6524658 (2021).","journal-title":"Biomed. Res. Int."},{"key":"2483_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.7150\/ntno.80030","volume":"7","author":"MZ Fahmi","year":"2023","unstructured":"Fahmi, M. Z. et al. In vivo study of chalcone loaded carbon Dots for enhancement of anticancer and bioimaging potencies. Nanotheranostics 7, 281\u2013298. https:\/\/doi.org\/10.7150\/ntno.80030 (2023).","journal-title":"Nanotheranostics"},{"key":"2483_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/0023677215573040","author":"M Wallace","year":"2015","unstructured":"Wallace, M. et al. Standard Operating Procedures in Experimental Liver Research: Thioacetamide model in mice and rats. Lab. Anim. 49, https:\/\/doi.org\/10.1177\/0023677215573040 (2015).","journal-title":"Lab. Anim."},{"key":"2483_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.592654","author":"B Salehi","year":"2021","unstructured":"Salehi, B. et al. Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence. Front. Pharmacol. 11, https:\/\/doi.org\/10.3389\/fphar.2020.592654 (2021).","journal-title":"Front. Pharmacol."},{"key":"2483_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/jhet.4395","volume":"59","author":"AH Abdelmonsef","year":"2022","unstructured":"Abdelmonsef, A. H. et al. A search for antiinflammatory therapies: synthesis, in Silico investigation of the mode of action, and in vitro analyses of new quinazolin\u20102, 4\u2010dione derivatives targeting phosphodiesterase\u20104 enzyme. J. Heterocycl. Chem. 59, 474\u2013492 (2022).","journal-title":"J. Heterocycl. Chem."},{"key":"2483_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0183680","volume":"12","author":"Y Lei","year":"2017","unstructured":"Lei, Y. et al. CHOP favors Endoplasmic reticulum stress-induced apoptosis in hepatocellular carcinoma cells via Inhibition of autophagy. PLoS One. 12, 1\u201317. https:\/\/doi.org\/10.1371\/journal.pone.0183680 (2017).","journal-title":"PLoS One"},{"key":"2483_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.22038\/IJBMS.2017.9273","volume":"20","author":"N Ghatei","year":"2017","unstructured":"Ghatei, N. et al. Evaluation of Bax, bcl-2, p21 and p53 genes expression variations on cerebellum of BALB\/c mice before and after birth under mobile phone radiation exposure. Iran. J. Basic. Med. Sci. 20, 1037. https:\/\/doi.org\/10.22038\/IJBMS.2017.9273 (2017).","journal-title":"Iran. J. Basic. Med. Sci."},{"key":"2483_CR28","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1007\/s00125-011-2093-9","volume":"54","author":"B Meissburger","year":"2011","unstructured":"Meissburger, B., Stachorski, L., R\u00f6der, E., Rudofsky, G. & Wolfrum, C. Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans. Diabetologia 54, 1468\u20131479. https:\/\/doi.org\/10.1007\/s00125-011-2093-9 (2011).","journal-title":"Diabetologia"},{"key":"2483_CR29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/jcp.36.5.609-d","volume":"36","author":"R Drury","year":"1983","unstructured":"Drury, R. & Techniques Theory and Practice of Histological J. Clin. Pathol. 36 609\u2013609. https:\/\/doi.org\/10.1136\/jcp.36.5.609-d. (1983).","journal-title":"J. Clin. Pathol."},{"key":"2483_CR30","doi-asserted-by":"publisher","DOI":"10.4081\/ejh.2016.2639","author":"M Malatesta","year":"2016","unstructured":"Malatesta, M. Histological and Histochemical Methods - Theory and practice. Eur. J. Histochem. 60, https:\/\/doi.org\/10.4081\/ejh.2016.2639 (2016).","journal-title":"Eur. J. Histochem."},{"key":"2483_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.01.051","author":"DK Mahapatra","year":"2015","unstructured":"Mahapatra, D. K., Asati, V. & Bharti, S. K. Chalcones and their therapeutic targets for the management of diabetes: Structural and pharmacological perspectives. Eur. J. Med. Chem. 92, https:\/\/doi.org\/10.1016\/j.ejmech.2015.01.051 (2015).","journal-title":"Eur. J. Med. Chem."},{"key":"2483_CR32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1139\/cjpp-2016-0071","volume":"94","author":"H Singh","year":"2015","unstructured":"Singh, H., Sidhu, S., Chopra, K. & Khan, M. U. Hepatoprotective effect of trans-Chalcone on experimentally induced hepatic injury in rats: Inhibition of hepatic inflammation and fibrosis. Can. J. Physiol. Pharmacol. 94, 879\u2013887. https:\/\/doi.org\/10.1139\/cjpp-2016-0071 (2015).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"2483_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.phrs.2017.11.022","volume":"129","author":"E Karimi-Sales","year":"2018","unstructured":"Karimi-Sales, E., Mohaddes, G. & Alipour, M. R. Chalcones as putative hepatoprotective agents: preclinical evidence and molecular mechanisms. Pharmacol. Res. 129, 177\u2013187. https:\/\/doi.org\/10.1016\/j.phrs.2017.11.022 (2018).","journal-title":"Pharmacol. Res."},{"key":"2483_CR34","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s10620-014-3167-6","volume":"59","author":"S Thapaliya","year":"2014","unstructured":"Thapaliya, S. et al. Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model. Dig. Dis. Sci. 59, 1197\u20131206. https:\/\/doi.org\/10.1007\/s10620-014-3167-6 (2014).","journal-title":"Dig. Dis. Sci."},{"key":"2483_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21249682","volume":"21","author":"L Shojaie","year":"2020","unstructured":"Shojaie, L., Iorga, A. & Dara, L. Cell death in liver diseases: A review. Int. J. Mol. Sci. 21, 1\u201347. https:\/\/doi.org\/10.3390\/ijms21249682 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2483_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30542","author":"JP Iredale","year":"2007","unstructured":"Iredale, J. P. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 117, https:\/\/doi.org\/10.1172\/JCI30542 (2007).","journal-title":"J. Clin. Invest."},{"key":"2483_CR37","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0168-8278(97)80454-0","volume":"26","author":"Y Murawaki","year":"1997","unstructured":"Murawaki, Y., Ikuta, Y., Idobe, Y., Kitamura, Y. & Kawasaki, H. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J. Hepatol. 26, 1213\u20131219. https:\/\/doi.org\/10.1016\/S0168-8278(97)80454-0 (1997).","journal-title":"J. Hepatol."},{"key":"2483_CR38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.274.5288.787","volume":"274","author":"DJ Van Antwerp","year":"1996","unstructured":"Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R. & Verma, I. M. Suppression of TNF-\u03b1-induced apoptosis by NF-\u03baB. Sci. (80-). 274, 787\u2013789. https:\/\/doi.org\/10.1126\/science.274.5288.787 (1996).","journal-title":"Sci. (80-)"},{"key":"2483_CR39","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.1038\/onc.2008.300","volume":"27","author":"B Sun","year":"2008","unstructured":"Sun, B. & Karin, M. NF-\u03baB signaling, liver disease and hepatoprotective agents. Oncogene 27, 6228\u20136244. https:\/\/doi.org\/10.1038\/onc.2008.300 (2008).","journal-title":"Oncogene"},{"key":"2483_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/192543","volume":"2010","author":"T Aoyama","year":"2010","unstructured":"Aoyama, T., Paik, Y-H. & Seki, E. Toll-Like receptor signaling and liver fibrosis. Gastroenterol. Res. Pract. 2010, 1\u20138. https:\/\/doi.org\/10.1155\/2010\/192543 (2010).","journal-title":"Gastroenterol. Res. Pract."},{"key":"2483_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2011.02.005","author":"UE Lee","year":"2011","unstructured":"Lee, U. E. & Friedman, S. L. Mechanisms of hepatic fibrogenesis, Best Pract. Res. Clin. Gastroenterol. 25, https:\/\/doi.org\/10.1016\/j.bpg.2011.02.005 (2011).","journal-title":"Res. Clin. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02483-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02483-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02483-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:09:51Z","timestamp":1757171391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02483-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2483"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02483-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The protocol of this study was approved by Research ethical committee of Theodor Bilharz Research Institute, No: PT (824). All animal studies were performed according to the principles of the Institutional Ethical Committee guidelines for treating experimental animals (FWA 00010609). The study investigated the impacts of the TTTE compound on necrosis in addition to fibrosis. This adjustment enabled an assessment of TTTE\u2019s therapeutic efficacy for liver injury treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"17546"}}